Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Inflammatory Bowel Diseases

Free Subscription 10.11.2025 2 Aliment Pharmacol Ther 2 Am J Gastroenterol 2 BMC Gastroenterol 1 Clin Gastroenterol Hepatol 2 Clin Res Hepatol Gastroenterol 1 Dig Dis Sci 2 Dis Colon Rectum 5 Inflamm Bowel Dis 3 J Clin Gastroenterol 1 J Crohns Colitis 1 J Gastroenterol 1 Minerva Gastroenterol (Torino) 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. GIRI S, Harindranath S, Chandnani S, Jena A, et al
   Systematic Review: Stigma Associated With Inflammatory Bowel Disease.
   Aliment Pharmacol Ther. 2025 Nov 4. doi: 10.1111/apt.70448.
   PubMed         Abstract available
   
   
2. PATEL P, Belesiotis P, Rai NS, Yuan Y, et al
   Meta-Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease.
   Aliment Pharmacol Ther. 2025 Nov 4. doi: 10.1111/apt.70446.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

3. RAO BB
   Continuing Medical Education Questions: November 2025.
   Am J Gastroenterol. 2025;120:2484.
   PubMed         Abstract available
   
   
4. YARUR AJ, Long MD, Torres J, Nandi N, et al
   Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical Program.
   Am J Gastroenterol. 2025;120:2611-2622.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

5. NAKATA R, Hosomi S, Kobayashi Y, Nishida Y, et al
   Ustekinumab enhances intestinal stenosis resolution by modulating fibrotic pathways in crohn's disease: a retrospective single-center study with translational analysis.
   BMC Gastroenterol. 2025;25:785.
   PubMed         Abstract available
   
   
6. XUE Y, Sun Y, Wu J, Chen B, et al
   Analysis of exercise behavior and influencing factors in patients with inflammatory bowel disease during remission and mild disease activity.
   BMC Gastroenterol. 2025;25:779.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

7. WEWER MD, Lophaven S, Lakatos PL, Gonczi L, et al
   Long-term disease course of Crohn's disease in a prospective European population-based inception cohort - an Epi-IBD cohort study.
   Clin Gastroenterol Hepatol. 2025 Nov 3:S1542-3565(25)00931.
   PubMed         Abstract available
   
   

   
   Clin Res Hepatol Gastroenterol

8. AMIOT A, Buisson A, Gornet JM, Fumery M, et al
   Diagnosis and management of patients with Crohn's disease. Position paper from the GETAID.
   Clin Res Hepatol Gastroenterol. 2025 Nov 1:102728.
   PubMed         Abstract available
   
   
9. BUISSON A, Denizot J
   Adherent-Invasive E. coli (AIEC) in Crohn's disease: where are we in 2025? Tribute to Professor Nicolas Barnich.
   Clin Res Hepatol Gastroenterol. 2025 Nov 4:102727.
   PubMed        
   
   

   
   Dig Dis Sci

10. VAN LIEROP LMA, Hoentjen F
    Incidental Inflammatory Bowel Disease: Is Surveillance and Treatment Needed?
    Dig Dis Sci. 2025 Nov 5. doi: 10.1007/s10620-025-09524.
    PubMed        
    
    

    
    Dis Colon Rectum

11. EISENSTEIN S
    Expert Commentary on Venous Thromboembolism Prophylaxis after Surgery in Patients With Inflammatory Bowel Disease.
    Dis Colon Rectum. 2025 Nov 6. doi: 10.1097/DCR.0000000000004033.
    PubMed        
    
    
12. XU Y, Song T, Cao L, Li Y, et al
    Impact of Sarcopenic Obesity on Postoperative Outcomes in Inflammatory Bowel Disease Patients with Bowel Resection Surgery: A Retrospective Cohort Study.
    Dis Colon Rectum. 2025 Nov 4. doi: 10.1097/DCR.0000000000004013.
    PubMed         Abstract available
    
    

    
    Inflamm Bowel Dis

13. JUN YK, Ji E, Choi Y, Shin CM, et al
    Trends and Impacts of Advanced Therapy on Chronic Opioid Use in Asian Patients with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Nov 4:izaf221. doi: 10.1093.
    PubMed         Abstract available
    
    
14. SELVAKUMAR B, Samsudin R
    Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Pathophysiology to Precision Therapeutics.
    Inflamm Bowel Dis. 2025 Nov 4:izaf225. doi: 10.1093.
    PubMed         Abstract available
    
    
15. DUBINSKY MC, D'Haens G, Dewit O, Juillerat P, et al
    Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease.
    Inflamm Bowel Dis. 2025 Nov 4:izaf250. doi: 10.1093.
    PubMed         Abstract available
    
    
16. KIM K, Ye BD
    Early Switching to Subcutaneous Infliximab as a Pragmatic Strategy for Optimized Inflammatory Bowel Disease Care.
    Inflamm Bowel Dis. 2025 Nov 4:izaf243. doi: 10.1093.
    PubMed        
    
    
17. 
    Correction to: Efficacy and Safety of Upadacitinib in a Case of Pediatric Acute Severe Ulcerative Colitis and Immune Thrombocytopenia.
    Inflamm Bowel Dis. 2025 Nov 2:izaf245. doi: 10.1093.
    PubMed        
    
    

    
    J Clin Gastroenterol

18. SHENOY S, Debroff J, Lacoste J, Giselbrecht E, et al
    Invisible Burdens: The Influence of Stigma and Social Determinants on Quality of Life in Perianal Fistulizing Crohn's Disease.
    J Clin Gastroenterol. 2025 Nov 3. doi: 10.1097/MCG.0000000000002275.
    PubMed         Abstract available
    
    
19. HEINLE JW, Kazzaz S, Schaefer EW, Liu G, et al
    Opioid Provision After Inpatient Care is Associated With Poor Outcomes in Inflammatory Bowel Disease.
    J Clin Gastroenterol. 2025 Nov 5. doi: 10.1097/MCG.0000000000002277.
    PubMed         Abstract available
    
    
20. KAHAN TF, Delau O, Hong S, Holmer A, et al
    Clostridioides difficile Infection Is Associated With Increased Colectomy Risk in Acute Severe Ulcerative Colitis Treated With Infliximab.
    J Clin Gastroenterol. 2025 Nov 10. doi: 10.1097/MCG.0000000000002276.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

21. INNOCENTI T, Hanzel J, Truyens M, Lukas M, et al
    Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class.
    J Crohns Colitis. 2025 Nov 3:jjaf188. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

22. YOSHIDA A, Takagi T, Kawashima K, Moriya K, et al
    Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study.
    J Gastroenterol. 2025 Nov 7. doi: 10.1007/s00535-025-02313.
    PubMed         Abstract available
    
    

    
    Minerva Gastroenterol (Torino)

23. MARTINO G, Lo Cascio A, Bozzetti M, Martino S, et al
    Validation of the Italian-Telemedicine Satisfaction Questionnaire in inflammatory bowel disease patients in Italy.
    Minerva Gastroenterol (Torino). 2025;71:181-193.
    PubMed         Abstract available
    
    

    
    PLoS One

24. NAZARI M, Goodarzi R, Yazdan Panah A, Amiri I, et al
    The protective role of Lactobacillus reuteri in a DSS-induced ulcerative colitis mouse model.
    PLoS One. 2025;20:e0335942.
    PubMed         Abstract available
    
    
25. CHEN H, Li N, Liu X, Ran M, et al
    Unveiling and verification of mitochondria-related genes as potential diagnostic biomarkers in ulcerative colitis based on bioinformatics analysis and experimental validation.
    PLoS One. 2025;20:e0336224.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.